Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 74
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
J Immunol ; 210(12): 1867-1881, 2023 Jun 15.
Artigo em Inglês | MEDLINE | ID: mdl-37186262

RESUMO

Recent studies have highlighted the pathogenic roles of IL-17-producing CD8+ T cells (T-cytotoxic 17 [Tc17]) in psoriasis. However, the underlying mechanisms of Tc17 induction remain unclear. In this study, we focused on the pathogenic subsets of Th17 and their mechanism of promotion of Tc17 responses. We determined that the pathogenic Th17-enriched fraction expressed melanoma cell adhesion molecule (MCAM) and CCR6, but not CD161, because this subset produced IL-17A abundantly and the presence of these cells in the peripheral blood of patients has been correlated with the severity of psoriasis. Intriguingly, the serial analysis of gene expression revealed that CCR6+MCAM+CD161-CD4+ T cells displayed the gene profile for adaptive immune responses, including CD83, which is an activator for CD8+ T cells. Coculture assay with or without intercellular contact between CD4+ and CD8+ T cells showed that CCR6+MCAM+CD161-CD4+ T cells induced the proliferation of CD8+ T cells in a CD83-dependent manner. However, the production of IL-17A by CD8+ T cells required exogenous IL-17A, suggesting that intercellular contact via CD83 and the production of IL-17A from activated CD4+ T cells elicit Tc17 responses. Intriguingly, the CD83 expression was enhanced in the presence of IL-15, and CD83+ cells stimulated with IL-1ß, IL-23, IL-15, and IL-15Rα did not express FOXP3. Furthermore, CCR6+MCAM+CD161-CD4+ T cells expressing CD83 were increased in the peripheral blood of patients, and the CD83+ Th17-type cells accumulated in the lesional skin of psoriasis. In conclusion, pathogenic MCAM+CD161- Th17 cells may be involved in the Tc17 responses via IL-17A and CD83 in psoriasis.

2.
Mod Rheumatol ; 34(2): 297-306, 2024 Feb 26.
Artigo em Inglês | MEDLINE | ID: mdl-37233722

RESUMO

OBJECTIVES: The aim of the article is to investigate the associations of disease duration and anti-cyclic citrullinated peptide antibody (ACPA) status with the effectiveness of abatacept in biologic-naïve patients with rheumatoid arthritis (RA). METHODS: We performed post hoc analyses of the Orencia® Registry in Geographically Assembled Multicenter Investigation (ORIGAMI) study of biologic-naïve RA patients aged ≥20 years with moderate disease activity who were prescribed abatacept. Changes in the Simplified Disease Activity Index (SDAI) and Japanese Health Assessment Questionnaire (J-HAQ) at 4, 24, and 52 weeks of treatment were analysed in patients divided according to ACPA serostatus (positive/negative), disease duration (<1/≥1 year), or both. RESULTS: SDAI scores decreased from baseline in all groups. SDAI scores tended to decrease more in the ACPA-positive group and disease duration <1-year group than in the ACPA-negative group and disease duration ≥1-year group, respectively. In the disease duration <1-year group, SDAI tended to decrease more in the ACPA-positive group than in the ACPA-negative group. Disease duration was independently associated with the change in SDAI and SDAI remission at Week 52 in multivariable regression models. CONCLUSIONS: These results suggest that starting abatacept within 1 year of diagnosis was associated with greater effectiveness of abatacept in biologic-naïve patients with RA and moderate disease activity.


Assuntos
Antirreumáticos , Artrite Reumatoide , Produtos Biológicos , Humanos , Abatacepte/uso terapêutico , Antirreumáticos/uso terapêutico , Japão , Resultado do Tratamento , Artrite Reumatoide/diagnóstico , Produtos Biológicos/uso terapêutico
3.
Rheumatology (Oxford) ; 60(1): 408-419, 2021 01 05.
Artigo em Inglês | MEDLINE | ID: mdl-32770199

RESUMO

OBJECTIVES: To determine the expression of hepatocyte growth factor (HGF) in RA biological fluids, the role of HGF in monocyte migration and the therapeutic effect of the c-Met inhibitor savolitinib in an arthritis model mice. METHODS: HGF/c-Met expression in serum, SF and synovial tissues (STs) obtained from RA patients and controls, as well as RA fibroblast-like synoviocytes (FLSs), was evaluated by ELISA and immunostaining. To determine the function of HGF in RA SF, we preincubated RA SF with a neutralizing anti-HGF antibody and measured the chemotactic ability of a human acute monocytic leukaemia cell line (THP-1). Additionally, examinations were conducted of SKG mice treated with savolitinib for 4 weeks. RESULTS: HGF levels in serum from RA patients were significantly higher than those in the controls and were decreased by drug treatment for 24 weeks. Additionally, the HGF level in SF from RA patients was higher than that in SF from OA patients. HGF and c-Met expression was also noted in RA STs. Stimulation of RA FLSs with TNF-α increased HGF/c-Met expression in a concentration-dependent manner, and c-Met signal inhibition suppressed production of fractalkine/CX3CL1 and macrophage inflammatory protein-1α/CCL3. When HGF was removed by immunoprecipitation, migration of THP-1 in RA SF was suppressed. In SKG mice, savolitinib significantly suppressed ankle bone destruction on µCT, with an associated reduction in the number of tartrate-resistant acid phosphatase-positive osteoclasts. CONCLUSION: HGF produced by inflammation in synovium of RA patients activates monocyte migration to synovium and promotes bone destruction via a chemotactic effect and enhanced chemokine production.


Assuntos
Artrite Reumatoide/metabolismo , Movimento Celular/efeitos dos fármacos , Fator de Crescimento de Hepatócito/metabolismo , Monócitos/metabolismo , Proteínas Proto-Oncogênicas c-met/metabolismo , Transdução de Sinais/efeitos dos fármacos , Adulto , Idoso , Idoso de 80 Anos ou mais , Animais , Artrite Reumatoide/sangue , Linhagem Celular Tumoral , Feminino , Fator de Crescimento de Hepatócito/sangue , Humanos , Inflamação/metabolismo , Masculino , Camundongos , Pessoa de Meia-Idade , Monócitos/efeitos dos fármacos , Osteoartrite/sangue , Osteoartrite/metabolismo , Proteínas Proto-Oncogênicas c-met/sangue , Membrana Sinovial/metabolismo
4.
Mod Rheumatol ; 27(5): 782-786, 2017 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-27846745

RESUMO

OBJECTIVES: A disintegrin and metalloproteinase (ADAM)-10 is expressed in rheumatoid arthritis (RA). In this study, we focused on ADAM-10 as a predictive factor for the treatment with biologics in RA. METHODS: The levels of ADAM-10 and fractalkine/CX3CL1 in RA and healthy controls serum were measured using enzyme-linked immunosorbent assays. Fifteen patients were treated with adalimumab (ADA), and 20 patients were treated with tocilizumab (TCZ). RESULTS: ADAM-10 positively correlated with fractalkine/CX3CL1 in the sera of RA patients and was presented at a significantly higher level compared to that in normal serum (487 ± 80 pg/ml and 85 ± 33 pg/ml, respectively, p < 0.05). ADAM-10 highly correlates with fractalkine/CX3CL1 in the sera of RA patients. The level of ADAM-10 decreased after the treatment with TCZ but not with ADA. In addition, we found that the level of ADAM-10 in TCZ responders was significantly higher than that of the TCZ nonresponders at 24 weeks (619 ± 134 pg/ml and 109 ± 25 pg/ml, respectively). Multiple regression analysis showed that ADAM-10 was only identified as independent predictive variable for the improvement of DAS28 (ESR) at 24 weeks. CONCLUSIONS: ADAM-10 may be a predictor of the effectiveness of TCZ in treating RA.


Assuntos
Proteína ADAM10/sangue , Anticorpos Monoclonais Humanizados , Artrite Reumatoide , Quimiocina CX3CL1/sangue , Quimiocina CXCL16/sangue , Adalimumab/administração & dosagem , Adalimumab/efeitos adversos , Idoso , Anticorpos Monoclonais Humanizados/administração & dosagem , Anticorpos Monoclonais Humanizados/efeitos adversos , Antirreumáticos/administração & dosagem , Antirreumáticos/efeitos adversos , Artrite Reumatoide/sangue , Artrite Reumatoide/tratamento farmacológico , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Prognóstico , Resultado do Tratamento
5.
Mod Rheumatol ; 26(5): 651-61, 2016 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26698929

RESUMO

OBJECTIVES: To investigate the efficacy and safety of etanercept (ETN) in patients with rheumatoid arthritis (RA) with moderate disease activity and the possibility to discontinue ETN after achieving remission. METHODS: Multicenter, randomized, and open-label study was conducted in Japan and Korea. RA patients (disease duration <5 years) with moderate disease activity despite methotrexate (MTX) treatment were allocated to either MTX or ETN + MTX (Period 1) for 12 months. Patients who achieved sustained remission defined as DAS28 < 2.6 at both 6 and 12 months in the ETN + MTX group, were randomized to either continue or discontinue ETN for 12 months (Period 2). RESULTS: A total of 222 patients were enrolled in Period 1 and clinical remission was achieved in 106/157 (67.5%) and 5/28 (17.9%) patients in the ETN + MTX and MTX groups, respectively. In Period 2, sixty-seven patients were randomized and finally 28/32 (87.5%) and 15/28 (53.6%) patients who continued or discontinued ETN maintained clinical remission. Baseline disease activity and the presence of comorbid diseases influenced the maintenance of remission after ETN discontinuation. CONCLUSIONS: ETN + MTX was efficient for RA patients with moderate disease activity into remission. After achieving sustained remission, a half of the patients who discontinued ETN could maintain remission for 1 year.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Etanercepte/uso terapêutico , Indução de Remissão/métodos , Adulto , Idoso , Artrite Reumatoide/diagnóstico , Quimioterapia Combinada , Feminino , Humanos , Japão , Masculino , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Estudos Prospectivos , República da Coreia , Índice de Gravidade de Doença , Resultado do Tratamento , Suspensão de Tratamento
6.
Mod Rheumatol ; 25(3): 480-3, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-24506660

RESUMO

A 68-year-old Japanese male presented with atrophic erythematous white lesions with peripheral dark reddish rims on his back. Multiple ulcers were detected from his stomach to his large intestine using endoscopy. Although the patient was given high doses of a steroid, aspirin, dipyridamole, and intravenous immunoglobulin therapy, he died of gastrointestinal hemorrhage, perforation and septic shock. An autopsy examination revealed pauci-inflammatory thrombotic microangiopathy with endothelial cell injury, fibrous occlusive arteriopathy, and vascular C5b-9 deposition in the wall of the gastrointestinal tract from the esophagus to the large intestine as well as in the dermis of the skin.


Assuntos
Complexo de Ataque à Membrana do Sistema Complemento/metabolismo , Trato Gastrointestinal/patologia , Papulose Atrófica Maligna/diagnóstico , Pele/patologia , Idoso , Evolução Fatal , Trato Gastrointestinal/metabolismo , Humanos , Masculino , Papulose Atrófica Maligna/metabolismo , Papulose Atrófica Maligna/patologia , Pele/metabolismo
7.
Rheumatol Int ; 34(3): 429-33, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-23670804

RESUMO

To examine the relationship between serum cytokine levels and response to tocilizumab in patients with RA. The disease status of 21 RA patients was assessed at baseline and after 12 weeks of tocilizumab treatment, using the clinical disease activity index (CDAI). Clinical response to tocilizumab was defined as an improvement of >50% from the baseline CDAI. Serum cytokine levels were quantified using double-ligand ELISA for TNF-α, IL-6, CCL2, CCL3, CXCL8, CXCL10, CX3CL1, and macrophage migration inhibitory factor (MIF). After 12 weeks of tocilizumab treatment, there was a significant overall reduction in RA disease activity (CDAI), from 22.4 ± 11.3 to 9.2 ± 6.6 (p < 0.0001), across the entire patient group. After 12 weeks of tocilizumab treatment, 14 patients achieved a >50% improvement (the responder group), but there were no significant responses in the other 7 patients (the non-responder group). The erythrocyte sedimentation rate levels, the positive % of anti-cyclic citrullinated protein antibody and patients (%) receiving methotrexate in combination with tocilizumab were significantly higher in the responder group than in the non-responder group. Although serum baseline levels of CCL2 and CXCL8 were higher in the responder group than in the non-responder group, there were no significant changes in these chemokine levels after treatment. The serum MIF levels, but not the levels of other cytokines, in the responder group were significantly decreased after tocilizumab treatment. Our results suggest that tocilizumab differentially regulates serum cytokine profiles in patients with RA, and MIF regulation in patients with active RA may be sensitive to anti-IL-6 therapy.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Artrite Reumatoide/sangue , Artrite Reumatoide/tratamento farmacológico , Fatores Inibidores da Migração de Macrófagos/sangue , Adulto , Idoso , Anticorpos Anti-Idiotípicos/sangue , Anticorpos Monoclonais Humanizados/imunologia , Sedimentação Sanguínea , Citocinas/sangue , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Peptídeos Cíclicos/imunologia , Receptores de Interleucina-6/imunologia , Estudos Retrospectivos , Índice de Gravidade de Doença , Resultado do Tratamento
8.
Mod Rheumatol ; 24(6): 939-44, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24670129

RESUMO

OBJECTIVE: Anti-ribosomal P protein antibody (anti-P) is detected in a fraction of systemic lupus erythematosus (SLE) patients, especially with lupus psychosis, lupus nephritis, and lupus hepatitis. However, it has been unclear whether anti-P testing is specific for SLE. The current studies were designed to examine the efficacy of serum anti-P testing in diagnosis of SLE. METHOD: Multicenter retrospective study was performed with 102 SLE patients, 102 patients with non-SLE rheumatic diseases, and 100 normal healthy subjects, who gave informed consents. The diagnosis of SLE was confirmed according to the 1982 ACR revised criteria. Serum IgG anti-P was determined by ELISA using the C-terminal 22 amino-acids of ribosomal P protein conjugated to human serum albumin. The specificity and sensitivity of anti-P were compared with those of anti-DNA, anti-Sm, and anti-cardiolipin (CL) antibodies. RESULTS: Serum anti-P was positive in 38 of 102 SLE patients (37.3%), in 4 of 102 patients with non-SLE rheumatic diseases (3.9%), and in none of 100 normal subjects. Receiver operating characteristic (ROC) curve analysis revealed that anti-P provided higher AUC (area under the curve) than anti-Sm or anti-CL. Consistently, the sensitivity of anti-P (37.3%) was superior to that of anti-Sm (27.5%) and anti-CL (24.5%), but inferior to that of anti-DNA (51.0%), whereas the specificity of anti-P (96.1%) was superior to that of anti-CL (86.3%) and comparable to that of anti-DNA (96.1%) and anti-Sm (96.1%). CONCLUSION: These results indicate that serum anti-P testing might be an effective measure in diagnosing SLE, providing better diagnostic efficiency than anti-Sm and anti-CL.


Assuntos
Autoanticorpos/sangue , Lúpus Eritematoso Sistêmico/diagnóstico , Doenças Reumáticas/diagnóstico , Proteínas Ribossômicas/imunologia , Adulto , Diagnóstico Diferencial , Feminino , Humanos , Lúpus Eritematoso Sistêmico/sangue , Lúpus Eritematoso Sistêmico/imunologia , Pessoa de Meia-Idade , Estudos Retrospectivos , Doenças Reumáticas/sangue , Doenças Reumáticas/imunologia , Sensibilidade e Especificidade
9.
Mod Rheumatol ; 23(5): 920-4, 2013 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-22990336

RESUMO

PURPOSE: Depression in rheumatoid arthritis (RA) patients is more severe than in healthy people. Herein, we report improved depression in RA patients using biologic agents. We examined whether depression was improved by tacrolimus combination therapy when biologic agents were ineffective. METHOD: The study included 13 RA patients who used biologic agents. The following methods were used before the initiation of tacrolimus combination therapy and at 14 and 30 weeks after treatment initiation: the Zung self-rating depression scale (SDS) to evaluate depression state, disease activity score 28/erythrocyte sedimentation rate (DAS28), tender joint counts, swollen joint counts, a patient global assessment to evaluate RA disease activity, and the modified health assessment questionnaire (mHAQ) to evaluate quality of life. RESULTS: The SDS scores before the initiation of tacrolimus combination therapy and at 14 and 30 weeks after treatment initiation were 45.2 ± 10.6, 44.8 ± 12.8, and 41.6 ± 11.2 (p = 0.047), respectively, indicating significant improvement. The DAS28 was 5.0 ± 1.3 prior to treatment, 3.8 ± 1.3 at 14 weeks, and 3.5 ± 0.9 at 30 weeks, demonstrating significant improvement at both 14 and 30 weeks (p < 0.001). The mHAQ score changed from 0.60 ± 0.45 at baseline to 0.54 ± 0.52 and 0.38 ± 0.43 at 14 and 30 weeks, respectively. The mHAQ score was significantly lower at 30 weeks when compared to baseline (p = 0.013). CONCLUSION: Tacrolimus combination therapy does not directly improve depression in RA patients, but it is possible that the observed improvement in depression accompanies the improvement in the secondary failure of RA.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Produtos Biológicos/uso terapêutico , Depressão/tratamento farmacológico , Tacrolimo/uso terapêutico , Adulto , Idoso , Antirreumáticos/administração & dosagem , Artrite Reumatoide/complicações , Artrite Reumatoide/psicologia , Produtos Biológicos/administração & dosagem , Depressão/complicações , Depressão/psicologia , Quimioterapia Combinada , Feminino , Nível de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Inquéritos e Questionários , Tacrolimo/administração & dosagem , Resultado do Tratamento
10.
Nihon Rinsho ; 71(7): 1218-24, 2013 Jul.
Artigo em Japonês | MEDLINE | ID: mdl-23961670

RESUMO

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by inflammation of the synovial joints, and eventual destruction of cartilage and bone, as well as various extra-articular signs and symptoms. The TNF-alpha blocker adalimumab (ADA) is a fully human IgG1 monoclonal antibody that neutralizes both soluble and membrane-bound TNF in humans. Several clinical trials have provided compelling evidence of the safety and clinical efficacy of ADA for both the induction and maintenance of remission in RA. Moreover, the beneficial effects of ADA on bone destruction seen in the joint of RA have been demonstrated by recent clinical investigation. This review will discuss the clinical efficacy and utility of ADA in the management of RA.


Assuntos
Anticorpos Monoclonais Humanizados/uso terapêutico , Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Adalimumab , Anticorpos Monoclonais Humanizados/efeitos adversos , Antirreumáticos/efeitos adversos , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/imunologia , Osso e Ossos/imunologia , Humanos , Inflamação/tratamento farmacológico
11.
Mod Rheumatol ; 22(1): 59-65, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-21607712

RESUMO

Macrophage migration inhibitory factor (MIF) is recognized to be an important mediator in several inflammatory disorders, including rheumatoid arthritis (RA) and vasculitis. To evaluate the role of MIF in rheumatoid vasculitis (RV), we determined serum levels of MIF by enzyme-linked immunosorbent assay in RA patients with and without vasculitis and assessed their relationship to disease activity. Serum was obtained from 95 RA patients during active disease states [49 without vasculitis, 35 with extra-articular manifestations without histologically proven vasculitis, and 11 with histologically proven vasculitis] and from 22 healthy individuals. Vasculitis disease activity was assessed using the Birmingham Vasculitis Activity Score (BVAS). MIF levels were significantly higher in RA patients than in controls. Moreover, MIF levels were significantly higher in RA patients with vasculitis than in those without vasculitic complications. In all RA patients, a statistically significant positive correlation was observed between serum MIF levels and each of the following: serum levels of C-reactive protein, rheumatoid factor, and thrombomodulin; and the erythrocyte sedimentation rate. In the RV group, the elevation of MIF levels correlated with the BVAS. Our findings suggest that MIF may serve as an additional serologic inflammatory marker of disease activity in RV, and it may be implicated in the pathogenesis of RV.


Assuntos
Artrite Reumatoide/sangue , Fatores Inibidores da Migração de Macrófagos/sangue , Vasculite/sangue , Idoso , Artrite Reumatoide/diagnóstico , Artrite Reumatoide/fisiopatologia , Biomarcadores/sangue , Ensaio de Imunoadsorção Enzimática , Feminino , Humanos , Masculino , Índice de Gravidade de Doença , Vasculite/diagnóstico , Vasculite/fisiopatologia
12.
Nihon Rinsho ; 70(1): 99-103, 2012 Jan.
Artigo em Japonês | MEDLINE | ID: mdl-22413501

RESUMO

The role of antidepressants in relieving pain and depression in rheumatic diseases are not clear. Specifically, higher depression has been shown to be related to higher pain, higher fatigue, and reduced quality of life for persons with rheumatic disease. At first, treat steroid, immunosuppressive agent and disease modifying anti-rheumatoid drug for rheumatic disease. When depression state does not improve even it, psychotropic drug (e.g., antidepressant drug, anti-anxiety agent, sleeping drug, etc) is used if necessary.


Assuntos
Depressão/tratamento farmacológico , Depressão/etiologia , Doenças Reumáticas/complicações , Humanos
13.
BMC Rheumatol ; 6(1): 75, 2022 Dec 17.
Artigo em Inglês | MEDLINE | ID: mdl-36527156

RESUMO

BACKGROUND: Assessing medication adherence in rheumatoid arthritis (RA) is clinically significant as low adherence is associated with high disease activity. Self-reported medication adherence surveys have been shown to have problems with overestimation of adherence due to social desirability bias. However, no MTX adherence studies adjusted for social desirability have been conducted to date. This study aimed to evaluate adherence to MTX and perform an investigatory search for factors associated with MTX adherence including social desirability. METHODS: This cross-sectional multicenter study was conducted among adult RA patients consuming oral MTX for ≥ 3 months. We examined the distribution of MTX adherence, according to the eight-item Morisky Medication Adherence Scale (MMAS-8). Social desirability was using the Social Desirability Scale (SDS). Furthermore, an exploratory factor analysis involving social desirability was examined to identify factors associated with MTX adherence using linear regression analysis. To deal with missing values, we used multiple imputations with chained equations methods. RESULTS: A total of 165 RA patients were enrolled. The median age was 64 years, and 86.1% were women. Based on the MMAS-8, low, medium, and high adherences were noted in 12.1%, 60.0%, and 27.9% of participants, respectively. High social desirability (coefficient, 0.14; 95% confidence interval [CI], 0.05-0.23; p < 0.05) and high age (coefficient per 10 years, 0.16; 95% CI, 0.01-0.03; p < 0.05) were associated with high MTX adherence, whereas full-time work was negatively associated with high MTX adherence (coefficient, -0.50; 95% CI, -0.95--0.05; p < 0.05). CONCLUSIONS: A large proportion of patients with RA do not take MTX as prescribed. High social desirability, high educational level, and non-full-time work may be associated with high MTX adherence. Physicians should confirm MTX adherence before switching or adding disease-modifying anti-rheumatic drugs in cases of uncontrolled disease activity.

14.
Sci Rep ; 11(1): 7937, 2021 04 12.
Artigo em Inglês | MEDLINE | ID: mdl-33846499

RESUMO

Eotaxin-1 (CCL11) induces the migration of different leukocyte types by interacting with CCR3. In rheumatoid arthritis (RA), fibroblast-like synoviocytes (FLS) are pathogenic effectors and a major CCR3-expressing cell. The aim of this study was to investigate the expression and function of CCL11 in RA FLS. The expression of CCL11 and CCR3 was evaluated by ELISA, immunofluorescence and quantitative PCR analysis. The CCL11 levels in serum and synovial fluids (SFs) from RA patients were significantly higher than those in serum from healthy controls and SFs from osteoarthritis patients. CCL11 and CCR3 were expressed in the RA synovial tissue lining layers. The secretion of CCL11 in RA FLS-conditioned medium and the mRNA expression of CCL11 and CCR3 were induced by TNF-α. Furthermore, CCL11 induced the mRNA expression of CCL11 and CCR3. Application of a CCR3 antagonist reduced TNF-α-induced CCL11 secretion from RA FLS. CCL11 induced the migration of RA FLS and monocytes. RA FLS migration was decreased by treatment with CCL11 siRNA. The migration of monocytes to medium conditioned with CCL11 siRNA-transfected and TNF-α-stimulated RA FLS was reduced. These data indicate that the self-amplification of CCL11 via CCR3 may play an important role in cell migration in RA.


Assuntos
Artrite Reumatoide/metabolismo , Artrite Reumatoide/patologia , Movimento Celular , Quimiocina CCL11/metabolismo , Artrite Reumatoide/sangue , Artrite Reumatoide/genética , Movimento Celular/efeitos dos fármacos , Quimiocina CCL11/sangue , Regulação da Expressão Gênica/efeitos dos fármacos , Humanos , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Receptores CCR3/genética , Receptores CCR3/metabolismo , Líquido Sinovial/metabolismo , Membrana Sinovial/metabolismo , Sinoviócitos/efeitos dos fármacos , Sinoviócitos/metabolismo , Células THP-1 , Fator de Necrose Tumoral alfa/farmacologia
15.
Rheumatol Ther ; 8(4): 1585-1601, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34448173

RESUMO

INTRODUCTION: Abatacept efficacy in older patients with rheumatoid arthritis (RA) has been primarily demonstrated via retrospective comparisons with younger patients. The objective of this study was to compare efficacy of abatacept in older vs. younger patients with RA, and efficacy of abatacept with that of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) in both age groups. METHODS: This prospective, multicenter, observational study (UMIN000014913) enrolled csDMARD-refractory patients without previous biological DMARD treatment. Abatacept (A) or csDMARDs (C) were administered at the treating physician's discretion to older (O, ≥ 65 years) and younger (Y, 20-64 years) patients, producing AO, AY, CO, and CY groups. Clinical efficacy after 24 weeks was evaluated using European League Against Rheumatism (EULAR) erythrocyte sedimentation rate response criteria. RESULTS: Overall, 202 patients were evaluated. Compared with the CO group, more patients in the AO group achieved a EULAR good or moderate response (p < 0.0001). Compared with the CY group, more patients in the AY group achieved a EULAR good or moderate response (p < 0.01). Similar proportions of patients in the AO and AY groups achieved a EULAR good response or a good or moderate response. Few adverse events were reported. CONCLUSIONS: This prospective study demonstrated that abatacept is efficacious and safe in older patients with RA and a history of being refractory to csDMARDs. Abatacept was shown to be more efficacious than adding or switching to a new csDMARD in both younger and older csDMARD-refractory patients with RA. TRIAL REGISTRATION: UMIN000014913.

16.
Mod Rheumatol ; 20(4): 420-2, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20376685

RESUMO

A 65-year-old Japanese woman, diagnosed with dermatomyositis with myopathy and characteristic skin lesion, was intravenously administered methylprednisolone 500 mg per day for 3 days, followed by prednisolone 60 mg po per day. Four days later, she went into shock. Computed tomography of the abdomen showed hematoma in the iliopsoas muscle on both sides and a thigh muscle. Intravenously administered heparin was stopped, and 4 U of packed cells and 4 U of fresh frozen plasma were transfused. The patient subsequently developed pulmonary edema requiring assisted ventilation, and made a successful recovery, returning home after a short period of intensive rehabilitation.


Assuntos
Dermatomiosite/complicações , Dermatomiosite/diagnóstico por imagem , Músculos Psoas/diagnóstico por imagem , Choque Hemorrágico/diagnóstico por imagem , Choque Hemorrágico/etiologia , Idoso , Anticoagulantes/uso terapêutico , Dermatomiosite/tratamento farmacológico , Feminino , Hematoma/diagnóstico por imagem , Hematoma/tratamento farmacológico , Hematoma/etiologia , Humanos , Imunossupressores/uso terapêutico , Músculos Psoas/irrigação sanguínea , Choque Hemorrágico/tratamento farmacológico , Coxa da Perna/irrigação sanguínea , Coxa da Perna/diagnóstico por imagem , Tomografia Computadorizada por Raios X
17.
Mod Rheumatol ; 20(6): 531-8, 2010 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-20574649

RESUMO

The superiority of the combination therapy of methotrexate (MTX) and anti-tumor necrosis factor (TNF) biological agents over anti-TNF monotherapy in MTX-naïve patients with rheumatoid arthritis (RA) has been demonstrated. We investigated the efficacy and safety of continuation versus discontinuation of MTX at the commencement of etanercept (ETN) in patients with active RA despite MTX therapy. In total, 151 patients with active RA despite treatment with MTX were randomized to either ETN 25 mg twice a week and MTX 6-8 mg/week (the E + M group) or ETN alone (the E group). Co-primary endpoints included the European League Against Rheumatism (EULAR) good response rate and the American College of Rheumatology (ACR) 50 response rate at week 24. Demographic and clinical features between groups at baseline were similar. The EULAR good response rates were significantly higher in the E + M group (52%) than in the E group (33%) at week 24 (p = 0.0001). Although the ACR50 response rate, one of the co-primary endpoints, and the ACR70 response rate at week 24 were not significantly greater in the E + M group (64 and 38%, respectively) than in the E group (48 and 26%, respectively), the ACR20 response rate was significantly greater in the E + M group (90%) than in the E group (64%; p = 0.0002). Safety profiles were similar for the groups. Thus, MTX should be continued at the commencement of ETN therapy, even in RA patients who show an inappropriate response to MTX.


Assuntos
Antirreumáticos/uso terapêutico , Artrite Reumatoide/tratamento farmacológico , Imunoglobulina G/uso terapêutico , Metotrexato/uso terapêutico , Receptores do Fator de Necrose Tumoral/uso terapêutico , Artrite Reumatoide/diagnóstico por imagem , Artrite Reumatoide/fisiopatologia , Artrografia , Progressão da Doença , Quimioterapia Combinada , Etanercepte , Feminino , Nível de Saúde , Humanos , Articulações/fisiopatologia , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Recuperação de Função Fisiológica , Resultado do Tratamento , Suspensão de Tratamento
18.
J Clin Med ; 9(12)2020 Nov 30.
Artigo em Inglês | MEDLINE | ID: mdl-33265990

RESUMO

Eosinophilic granulomatosis with polyangiitis (EGPA) is a type of systemic vasculitis with eosinophilia in the peripheral blood, which is preceded by bronchial asthma or allergic disease. EGPA is pathologically characterized by microangiopathy granulomatosis vasculitis. Vasculitis can be exacerbated and cause central nervous system and cardiovascular disorders and gastrointestinal perforation. Histological examination reveals eosinophil infiltration and granulomas in lesions in areas such as the lung, nervous system, and skin. Laboratory tests show inflammatory findings such as C-reactive protein (CRP) elevation, increased eosinophils, elevated serum IgE, and elevated myeloperoxidase-anti-neutrophil cytoplasmic antibodies (MPO-ANCA). MPO-ANCA is positive in approximately 40-70% of cases of this disease. EGPA is a necrotizing vasculitis that affects small- and medium-sized blood vessels; however, it differs from other types of ANCA-related vasculitis (such as microscopic polyangiitis and granulomatosis) because it is preceded by bronchial asthma and eosinophilia in the blood and tissues. Treatment with immunosuppressive agents such as steroids or cyclophosphamide depends on the Five Factor Score, which predicts the prognosis and severity of the condition. If the effect of appropriate treatment with steroids is insufficient, the anti-interleukin-5 antibody mepolizumab can be administered. The combination of mepolizumab with standard treatment leads to a significantly longer duration of remission, a higher proportion of patients who achieve sustained remission, and less steroid use than with a placebo.

19.
Int J Rheum Dis ; 23(10): 1328-1336, 2020 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-32896992

RESUMO

AIMS: We compared the incidence of adverse events between single and divided-dose regimens of methotrexate (MTX) by using a multicenter randomized controlled trial. METHODS: Eighty-nine patients with insufficient control on MTX 8 mg/wk were randomly assigned into single-dose (39 patients) or triple dose (39 patients) groups. The MTX dose for all patients was gradually increased to 16 mg/wk. The primary endpoint was the occurrence of liver dysfunction during the observation period (20 weeks). RESULTS: There were no differences in baseline data and MTX dose at Week 20 between groups. There was no significant difference in the incidence of liver dysfunction between groups (single dose, 3 [7.7%] patients vs. triple dose, 5 [13.2%] patients; P = .455). The incidence of adverse event increased in triple dose (single dose, 12 [30.8%] patients vs. triple dose, 20 [51.3%]), but the difference was not significant (P = .066). There was no significant difference in disease activity between groups, although MTX-triglutamate (PG3), MTX-PG4, and MTX-PG5 were significantly higher in the single dose group. CONCLUSIONS: Weekly split dosing reduced the polyglutamation of MTX. There was no significant difference in efficacy and safety between the 2 groups.


Assuntos
Artrite Reumatoide/tratamento farmacológico , Eritrócitos/metabolismo , Metotrexato/administração & dosagem , Ácido Poliglutâmico/sangue , Administração Oral , Antirreumáticos/administração & dosagem , Artrite Reumatoide/sangue , Relação Dose-Resposta a Droga , Esquema de Medicação , Eritrócitos/efeitos dos fármacos , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Ácido Poliglutâmico/efeitos dos fármacos , Resultado do Tratamento
20.
Patient Saf Surg ; 14: 24, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32518591

RESUMO

BACKGROUND: Hospitals deliver 24-h, 7-day care on a 5-day workweek model, as fewer resources are available on weekends. In prior studies, poorer outcomes have been observed with weekend admission or surgery. The purpose of this study was to investigate the effect of 7-day service at a hospital, including outpatient consultations, diagnostic examinations and elective surgeries, on the likelihood of the "weekend effect" in surgery. METHODS: This was a retrospective cohort study of patients who underwent surgery between April 2014 and October 2016 at an academic medical centre in Tokyo, Japan. The main outcome measure was 30-day in-hospital mortality from the index surgery. The characteristics of the participants were compared using the Mann-Whitney U test or the chi-squared test as appropriate. Logistic regression was used to test for differences in the mortality rate between the two groups, and propensity score adjustments were made. RESULTS: A total of 7442 surgeries were identified, of which, 1386 (19%) took place on the weekend. Of the 947 emergency surgeries, 25% (235) were performed on the weekend. The mortality following emergency weekday surgery was 21‰ (15/712), compared with 55‰ (13/235) following weekend surgery. Of the 6495 elective surgeries, 18% (1151) were performed on the weekend. The mortality following elective weekday surgery was 2.3‰ (12/5344), compared with 0.87‰ (1/1151) following weekend surgery. After adjustment, weekend surgeries were associated with an increased risk of death, especially in the emergency setting (emergency odds ratio: 2.7, 95% confidence interval: 1.2-6.5 vs. elective odds ratio: 0.4, 95% confidence interval: 0.05-3.2). CONCLUSIONS: Patients undergoing emergency surgery on the weekend had higher 30-day mortality, but showed no difference in elective surgery mortality. These findings have potential implications for health administrators and policy makers who may try to restructure the hospital workweek or consider weekend elective surgery.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA